BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure

Reuters

2025/12/11

BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure

BeyondSpring Inc. announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study, evaluating Plinabulin in combination with docetaxel for patients with EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) who have progressed after anti-PD-$(L)$1 immunotherapy. The results, presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer (NACLC), showed that the combination of Plinabulin and docetaxel provided clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone. Specifically, median overall survival was 15.8 months for the combination versus 11.7 months for docetaxel alone, with a hazard ratio of 0.55. Median progression-free survival was 5.6 months versus 3.8 months (HR=0.67), and the objective response rate was 18.2% versus 8.0%. The company also reported reductions in brain metastasis and a substantial improvement in metastasis-free survival. BeyondSpring plans to initiate the global Phase 3 DUBLIN-4 trial as a confirmatory study to support a future new drug application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600547) on December 11, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2590518274"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590518274\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590518274?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590518274","market":"nz","top_or_hot":-1,"title":"BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeyondSpring Inc. announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study, evaluating Plinabulin in combination with docetaxel for patients with EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) who have progressed after anti-PD-<a href=\"https://laohu8.com/S/L\">$(L)$</a>1 immunotherapy. The results, presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer (NACLC), showed that the combination of Plinabulin and docetaxel provided clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone. Specifically, median overall survival was 15.8 months for the combination versus 11.7 months for docetaxel alone, with a hazard ratio of 0.55. Median progression-free survival was 5.6 months versus 3.8 months (HR=0.67), and the objective response rate was 18.2% versus 8.0%. The company also reported reductions in brain metastasis and a substantial improvement in metastasis-free survival. BeyondSpring plans to initiate the global Phase 3 DUBLIN-4 trial as a confirmatory study to support a future new drug application.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600547) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BeyondSpring Inc. announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study, evaluating Plinabulin in combination with docetaxel for patients with EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) who have progressed after anti-PD-<a href=\"https://laohu8.com/S/L\">$(L)$</a>1 immunotherapy. The results, presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer (NACLC), showed that the combination of Plinabulin and docetaxel provided clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone. Specifically, median overall survival was 15.8 months for the combination versus 11.7 months for docetaxel alone, with a hazard ratio of 0.55. Median progression-free survival was 5.6 months versus 3.8 months (HR=0.67), and the objective response rate was 18.2% versus 8.0%. The company also reported reductions in brain metastasis and a substantial improvement in metastasis-free survival. BeyondSpring plans to initiate the global Phase 3 DUBLIN-4 trial as a confirmatory study to support a future new drug application.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600547) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BYSI","symbol_name":"万春药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1qwhfK:1","article_id":"2590518274","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590518274","pubTimestamp":1765454522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BeyondSpring Inc. announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study, evaluating Plinabulin in combination with docetaxel for patients with EGFR wild-type non-squamous non-small cell lung cancer  who have progressed after anti-PD-1 immunotherapy. The results, presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer , showed that the combination of Plinabulin and docetaxel provided clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone. Specifically, median overall survival was 15.8 months for the combination versus 11.7 months for docetaxel alone, with a hazard ratio of 0.55. Median progression-free survival was 5.6 months versus 3.8 months , and the objective response rate was 18.2% versus 8.0%. The company also reported reductions in brain metastasis and a substantial improvement in metastasis-free survival. BeyondSpring plans to initiate the global Phase 3 DUBLIN-4","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BYSI":"万春药业","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","NDAQ":"纳斯达克OMX交易所"},"translate_title":"BeyondSpring报道普那布林联合多西他赛改善EGFR野生型非小细胞肺癌在检查点抑制剂失败后的生存率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BYSI":0.9},"content_text":"BeyondSpring Reports Plinabulin Plus Docetaxel Improves Survival in EGFR Wild-Type NSCLC After Checkpoint Inhibitor Failure\n    \n\n        BeyondSpring Inc. announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study, evaluating Plinabulin in combination with docetaxel for patients with EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) who have progressed after anti-PD-$(L)$1 immunotherapy. The results, presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer (NACLC), showed that the combination of Plinabulin and docetaxel provided clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone. Specifically, median overall survival was 15.8 months for the combination versus 11.7 months for docetaxel alone, with a hazard ratio of 0.55. Median progression-free survival was 5.6 months versus 3.8 months (HR=0.67), and the objective response rate was 18.2% versus 8.0%. The company also reported reductions in brain metastasis and a substantial improvement in metastasis-free survival. BeyondSpring plans to initiate the global Phase 3 DUBLIN-4 trial as a confirmatory study to support a future new drug application.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600547) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}